Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMFDBV5)

Drug Name
NPT200-11 Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple system atrophy 8D87.0 Phase 1 [1]
Parkinson disease 8A00.0 Phase 1 [1]
Cross-matching ID
PubChem CID
146420437
TTD Drug ID
DMFDBV5

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Synuclein alpha (SNCA) TT08OSU SYUA_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Synuclein alpha (SNCA) DTT SNCA 5.221 5.594 5.585 5.781
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Multiple system atrophy
ICD Disease Classification 8D87.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Synuclein alpha (SNCA) DTT SNCA 1.04E-01 -0.26 -0.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Sci Rep. 2018 Nov 1;8(1):16165.